

<b>Statement of Deficiencies</b>	<b>(X1) Provider/Supplier/CLIA Identification Number</b>  17D0046990	<b>(X3) Date Survey Completed</b>  10/19/2021
<b>Name of Provider or Supplier</b>  Hospital District No 6 Of Harper County	<b>Street Address, City, State</b>  485 N Ks Hwy 2, Anthony, KS	
For information on the provider's plan to correct this deficiency, please contact the provider or the state survey agency.		

<b>(X4) ID Prefix Tag</b>	<b>Summary Statement of Deficiencies</b>
<b>D2016</b>	<p><b>SUCCESSFUL PARTICIPATION</b> CFR(s): 493.803(a)(b)(c)</p> <p>(a) Each laboratory performing nonwaived testing must successfully participate in a proficiency testing program approved by CMS, if applicable, as described in subpart I of this part for each specialty, subspecialty, and analyte or test in which the laboratory is certified under CLIA. (b) Except as specified in paragraph (c) of this section, if a laboratory fails to participate successfully in proficiency testing for a given specialty, subspecialty, analyte or test, as defined in this section, or fails to take remedial action when an individual fails gynecologic cytology, CMS imposes sanctions, as specified in subpart R of this part. (c) If a laboratory fails to perform successfully in a CMS-approved proficiency testing program, for the initial unsuccessful performance, CMS may direct the laboratory to undertake training of its personnel or to obtain technical assistance, or both, rather than imposing alternative or principle sanctions except when one or more of the following conditions exists: (1) There is immediate jeopardy to patient health and safety. (2) The laboratory fails to provide CMS or a CMS agent with satisfactory evidence that it has taken steps to correct the problem identified by the unsuccessful proficiency testing performance. (3) The laboratory has a poor compliance history.</p> <p>This CONDITION is not met as evidenced by: Based on the review of proficiency testing (PT) records from American Proficiency Institute (API), the laboratory failed to successfully participate in PT for the analyte: Cell identification or White blood cell differential for two out of three consecutive proficiency testing events: 2020 Event 3 and 2021 Event 2 (refer to D2131).</p>
<b>D2131</b>	<p><b>HEMATOLOGY</b> CFR(s): 493.851(g)</p> <p>Failure to achieve an overall testing event score of satisfactory performance for two</p>

consecutive testing events or two out of three consecutive testing events is unsuccessful performance.

This STANDARD is not met as evidenced by:

A PT desk review and phone interview on 10/19/21 revealed the laboratory failed to successfully participate in PT from API for the analyte: Cell identification or White blood cell differential. Findings: 1. Review of the 2020 API 3rd Event revealed a score of 68% for Cell identification or White blood cell differential. 2. Review of the 2021 API 2nd Event revealed a score of 64% for Cell identification or White blood cell differential. 3. Phone interview 10/19/21 at 8:20 a.m. with the general supervisor confirmed, the laboratory failed to successfully participate in PT from API for the analyte: Cell identification or White blood cell differential.